Katyna Borroto–Esoda

Author

Also Known As

K BORROTOESODA, K Borroto-Esoda, K Borroto‐Esoda, K. Borroto-Esoda, K. Borroto‐Esoda, Katyna Borroto-Esoda, Katyna Borroto‐Esoda, Katyna Borroto–Esoda, Sheahan, Timothy P.

115

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)Scynexis (United States)Case Western Reserve University University Hospitals of Cleveland Hôpital Beaujon

About

Katyna Borroto–Esoda is an author at Gilead Sciences (United States) specializing in medicine, hepatitis, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	2K
2	Natural Sciences	3	3	63
3	Public Health	1	1	29
4	Biochemistry	1	1	19
5	Biomolecular Engineering	1	1	13

Katyna Borroto–Esoda

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote, Gastroenterology HepatologyViral HepatitisPharmacologyHepatitis BHepatitis	2006	882
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B E. Jenny Heathcote, Patrick Marcellin, Edward Gane, Gastroenterology HepatologyViral HepatitisMedicineHepatitis BHepatitis	2010	461
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation Emily L. Larkin, Christopher Hager, Jyotsna Chandra, Antimicrobial Agents and Chemotherapy	2017	378
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus William A. Fischer, Joseph J. Eron, Wayne Holman, Science Translational Medicine	2021	348
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B Patrick Marcellin, Ting‐Tsung Chang, Seng Gee Lim, Hepatology	2008	310
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP) Koichi Watashi, Ann E. Sluder, Takuji Daito, Hepatology	2013	253
Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B Eugene R. Schiff, Ching‐Lung Lai, Stephanos J. Hadziyannis, Liver Transplantation	2007	236
No Detectable Resistance to Tenofovir Disoproxil Fumarate After 6 Years of Therapy in Patients With Chronic Hepatitis B Kathryn M. Kitrinos, Amoreena C. Corsa, Yang Liu, Hepatology	2013	225
Molnupiravir, an Oral Antiviral Treatment for COVID-19 William A. Fischer, Joseph J. Eron, Wayne Holman,	2021	215
No Resistance to Tenofovir Disoproxil Fumarate Detected After up to 144 Weeks of Therapy in Patients Monoinfected With Chronic Hepatitis B Virus Δ Andrea Snow‐Lampart, Brandi Chappell, Maria Curtis, Hepatology	2010	177

Page 1